Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21419553 | 1.00 | CYP1B1 (0.45) | CYP1B1CYP19A1CHRM5ADRA2CCHRM2 | |
| SCHEMBL19176752 | 1.00 | CYP1B1 (0.45) | CYP1B1CYP19A1CHRM5ADRA2CCHRM2 | |
| SCHEMBL20365061 | 0.93 | CYP1B1 (0.44) | CYP1B1CYP19A1TRPA1OPRL1MGLL | |
| Bicarbonate SCHEMBL2319198 | 0.92 | TRPA1 (0.46) | CYP1B1CYP19A1TRPA1OPRL1 | |
| SCHEMBL485615 | 0.89 | MGLL (0.44) | CYP1B1MGLLALDH1A1NPSR1LMNA | |
| SCHEMBL3828808 | 0.87 | CYP1B1 (0.40) | CYP1B1CYP19A1TRPA1MGLLALDH1A1 | |
| SCHEMBL29050171 | 0.82 | MGLL (0.44) | CYP1B1MGLLALDH1A1NPSR1LMNA | |
| SCHEMBL18279974 | 0.82 | TRPA1 (0.40) | CYP1B1TRPA1ALDH1A1 | |
| SCHEMBL17961058 | 0.81 | MGLL (0.38) | CYP1B1MGLLALDH1A1NPSR1LMNA | |
| SCHEMBL24218198 | 0.79 | MGLL (0.46) | MGLLALDH1A1NPSR1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719485-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | Taimed Biologics Inc. (TW) | 2026-04-08 | — | — | EP | claimed |
| US-20240398969-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | TAIMED BIOLOGICS INC. (TW) | 2024-12-05 | — | — | US | claimed |
| WO-2024245401-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | TAIMED BIOLOGICS INC. (CN) | 2024-12-05 | — | — | WO | claimed |
| CN-118256088-A | Resin composition and application thereof | 广东生益科技股份有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118240341-A | Thermosetting resin composition and application thereof | 广东生益科技股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-118240342-A | Thermosetting resin composition and application thereof | 广东生益科技股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117813286-A | Novel bismaleimide compounds with improved solubility and their use in curable compositions | 赢创运营有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-117624837-A | Resin composition, and prepreg, metal foil laminate and printed wiring board produced using the same | 台燿科技股份有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-111690247-B | Resin composition and use thereof | 台燿科技股份有限公司 | 2024-01-02 | — | — | CN | claimed |
| WO-2020028840-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA | DYNE THERAPEUTICS, INC. (US) | 2020-02-06 | — | — | WO | claimed |
| WO-2020028864-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2020-02-06 | — | — | WO | claimed |
| WO-2020028857-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | DYNE THERAPEUTICS, INC. (US) | 2020-02-06 | — | — | WO | claimed |
| WO-2020028841-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING POMPE DISEASE | DYNE THERAPEUTICS, INC. (US) | 2020-02-06 | — | — | WO | claimed |
| WO-2020028831-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | DYNE THERAPEUTICS, INC. (US) | 2020-02-06 | — | — | WO | claimed |
| WO-2020028832-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | DYNE THERAPEUTICS, INC. (US) | 2020-02-06 | — | — | WO | claimed |
| EP-2948478-B1 | ANTIBODIES TARGETING CDH19 FOR MELANOMA | AMGEN INC (US) | 2019-04-03 | — | — | EP | claimed |
| EP-2734239-A2 | LONG ACTING LUTEINIZING HORMONE (LH) COMPOUND | Arts Biologics A/S (DK) | 2014-05-28 | — | — | EP | claimed |
| WO-2013010840-A2 | LONG ACTING BIOLOGICALLY ACTIVE LUTEINIZING HORMONE (LH) COMPOUND | ARTS BIOLOGICS A/S (DK) | 2013-01-24 | — | — | WO | claimed |
| CN-1764478-A | Anti-cancer anthracycline drug-antibody conjugates | IMMUNOMEDICS INC (US) | 2006-04-26 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398969-A1 | ANTIBODY-DRUG CONJUGATES FOR TREATING INFECTIONS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | CD4, FCGR3B, FCGR1A | CYP1B1 4046/4885CYP19A1 3347/4885CHRM5 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.